Endocrine Abstracts

Introduction: Type 2 diabetes mellitus (T2DM) and cancer commonly occur together, either because of direct association or merely as both diseases are common among the elderly. The presence of either T2DM itself, or its treatment may affect cancer progression outcomes and response to cancer therapy. Immune-checkpoint inhibitors (ICIs) have become the cornerstone of treatment of several malignancies, including non-small cell lung cancer (NSCLC). As T2DM has been shown to suppres...